Harrow, Inc. announced the execution of a five-year strategic supply and development (SSD) agreement for TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL. This agreement is crucial for securing the long-term supply chain of the FDA-approved, preservative-free synthetic corticosteroid.
TRIESENCE is indicated for visualization during vitrectomy and for the treatment of ocular inflammatory conditions unresponsive to topical corticosteroids. The SSD agreement ensures consistent availability of this product, which had previously faced supply chain challenges and was on the FDA Drug Shortage List for over five years.
This strategic move is expected to support Harrow's commercial efforts for TRIESENCE, allowing ophthalmologists to confidently rely on its availability. The agreement underscores Harrow's commitment to providing essential ophthalmic medications and strengthening its product portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.